0000950103-16-016765.txt : 20160930 0000950103-16-016765.hdr.sgml : 20160930 20160930171641 ACCESSION NUMBER: 0000950103-16-016765 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20160930 DATE AS OF CHANGE: 20160930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biotie Therapies Corp. CENTRAL INDEX KEY: 0001579695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: H9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37423 FILM NUMBER: 161913574 BUSINESS ADDRESS: STREET 1: JOUKAHAISENKATU 6 CITY: TURKU STATE: H9 ZIP: FI-20520 BUSINESS PHONE: 358-2-274-8900 MAIL ADDRESS: STREET 1: JOUKAHAISENKATU 6 CITY: TURKU STATE: H9 ZIP: FI-20520 6-K 1 dp68139_6k.htm FORM 6-K

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September, 2016

______________

 

Commission File Number: 001-37423

 

Biotie Therapies Oyj 

(Exact name of registrant as specified in its charter)

 

Biotie Therapies Corp. 

(Translation of registrant’s name into English)

 

Joukahaisenkatu 6, FI-20520 

Turku, Finland 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒   Form 40-F  

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes     No ☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes   No ☒

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    BIOTIE THERAPIES CORP.
     
     
      By: /s/ Kristian Rantala
        Name: Kristian Rantala
        Title: Chief Financial Officer

Date: September 30, 2016

 

 

 

 

EXHIBIT INDEX

 

Exhibit
Number		 Description
99.1 Stock Exchange Release dated  September 30, 2016 (2:15 p.m. EET):  ACORDA THERAPEUTICS, INC. GAINS TITLE TO ALL SHARES IN BIOTIE THERAPIES CORP. AND THE SHARES WILL DELIST FROM NASDAQ HELSINKI

 

 

 

 

 EX-99.1 2 dp68139_ex9901.htm EXHIBIT 99.1

Exhibit 99.1

 

BIOTIE THERAPIES CORP. STOCK  EXCHANGE RELEASE 30 September  2016, at 2.15 p.m. (EET)

 

 

ACORDA THERAPEUTICS, INC. GAINS TITLE TO ALL SHARES IN BIOTIE THERAPIES CORP. AND THE SHARES WILL DELIST FROM NASDAQ HELSINKI

 

Acorda Therapeutics, Inc. (Nasdaq: ACOR) (”Acorda”) has today lodged security approved by the Arbitral Tribunal and thus gained title to all the shares in Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie”) in accordance with Chapter 18, Section 6 of the Finnish Companies Act. After the security has been lodged, the minority shareholders of Biotie being parties to the redemption proceedings are only entitled to receive the redemption price and the interest payable thereon.

 

Upon application by Biotie, Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) has on 25 August 2016 decided that the Biotie shares will be delisted from the Official List of Nasdaq Helsinki upon title to all shares in Biotie having been transferred to Acorda. The quoting of the Biotie shares on Nasdaq Helsinki will thus cease in accordance with a separate release to be published by Nasdaq Helsinki.

 

Turku, 30 September 2016

 

Biotie Therapies Corp.

Antero Kallio
CEO

 

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

 

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

 

INFORMATION REGARDING BIOTIE

 

Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. Biotie is a subsidiary of Acorda Therapeutics, Inc. ("Acorda") and its shares, excluding of those owned by Acorda, are currently subject to a redemption process in accordance with the Finnish Companies Act.

 

For more information, please visit www.biotie.com.

 

INFORMATION REGARDING ACORDA

 

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

 

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, post-stroke walking difficulties, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

 

For more information, please visit www.acorda.com.